Clinical and basic researchers applying cutting-edge technologies to study the pathogenesis and therapeutic innovations of viral-related liver diseases.

Select Publications

Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.
Ma CD, Imamura M, Talley DC, Rolt A, Xu X, Wang AQ, Le D, Uchida T, Osawa M, Teraoka Y, Li K, Hu X, Park SB, Chalasani N, Irvin PH, Dulcey AE, Southall N, Marugan JJ, Hu Z, Chayama K, Frankowski KJ, Liang TJ.
Nat Microbiol (2020 Dec) 5:1532-1541. Abstract/Full Text
Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.
Cheng X, Uchida T, Xia Y, Umarova R, Liu CJ, Chen PJ, Gaggar A, Suri V, Mücke MM, Vermehren J, Zeuzem S, Teraoka Y, Osawa M, Aikata H, Tsuji K, Mori N, Hige S, Karino Y, Imamura M, Chayama K, Liang TJ.
J Clin Invest (2020 Jun 1) 130:3205-3220. Abstract/Full Text
View More Publications